Quarterly ResultAug 6, 2026, 05:14 PM
Apyx Medical Q2 Sales $13.88M, Net Loss $(3.24)M; FDA Clearance
AI Summary
Apyx Medical reported Q2 2026 net sales of $13.88 million, an increase from $11.37 million in the prior year, with net loss attributable to stockholders improving to $(3.24) million from $(3.78) million. The company received expanded FDA 510(k) clearance for its AYON Body Contouring System™ to include power liposuction, commencing a limited commercial launch. Despite improved sales and narrowed losses, the company continues to incur recurring net losses and increased cash outflows from operations, raising liquidity concerns. Additionally, Apyx Medical is involved in ongoing product liability lawsuits and a new patent infringement lawsuit.
Key Highlights
- Q2 2026 net sales increased to $13.88 million from $11.37 million in Q2 2025.
- Q2 2026 net loss attributable to stockholders improved to $(3.24) million from $(3.78) million.
- Received expanded FDA 510(k) clearance for AYON Body Contouring System™ power liposuction.
- Net cash used in operating activities for H1 2026 was $(4.06) million, up from $(1.94) million.
- Cash and cash equivalents stood at $27.62 million as of June 30, 2026.
- Surgical Aesthetics segment sales were $12.39 million in Q2 2026, up from $9.67 million.
- OEM segment sales were $1.50 million in Q2 2026, down from $1.70 million.
- Company faces ongoing product liability and a new patent infringement lawsuit.
Price Impact
More from APYX